Bank of America
SLXN

Bank of America’s Silexion Therapeutics SLXN Stock Holding History

Bank of America’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$405 – 8767
2025
Q2 		$405 Hold
3
– – ﹤0.01% 7710
2025
Q1 		$550 Buy
+3
New +$594 ﹤0.01% 7505

Other funds holding SLXN

MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Bank of America's SLXN Position: Q3 2025 in Review

Bank of America sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 3 shares — an estimated $405 sold.

Bank of America first reported a position in SLXN in Q1 2025 and held it in 2 quarters. The position peaked at $550 in Q1 2025. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

  • Bank of America reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 3 Silexion Therapeutics shares in Q3 2025, an estimated $405.
  • Bank of America first reported a position in Silexion Therapeutics in Q1 2025 and held it in 2 quarters.
  • Bank of America's Silexion Therapeutics position peaked at $550 in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.